现在的位置: 首页 >研究点评, 进展交流>正文
[Lancet Neurol发表述评]:地塞米松治疗单纯疱疹病毒脑炎
2026年11月21日 ⁄ 研究点评, 进展交流 ⁄ [Lancet Neurol发表述评]:地塞米松治疗单纯疱疹病毒脑炎已关闭评论

Comment

Dexamethasone in herpes simplex virus encephalitis: timely insights amid study limitations

Thais Armangue, Josep Dalmau

Lancet Neurol 2026; 25: 116-117

https://doi.org/10.1016/S1474-4422(25)00484-3

Herpes simplex virus (HSV) encephalitis, caused by HSV types 1 and 2, is the most common sporadic viral encephalitis worldwide, with an annual incidence of around 2·2–4·6 per million people.1 Before aciclovir, mortality approached 70%; with antiviral therapy, it has dropped to 10–15%,1 although up to 90% of survivors do not regain premorbid function.2

Mortality is highest in the first 2 weeks, driven by viral necrosis with inflammation, oedema, and microhaemorrhages, sometimes requiring surgical decompression. Refractory seizures, status epilepticus, and systemic complications in patients with critical illness further increase the risk of death,3 and delayed antiviral therapy, immunosuppression, and older age are predictors of poor outcome.4

Post-infectious autoimmune encephalitis complicates 20–25% of HSV encephalitis cases, typically 3–8 weeks after diagnosis. The condition causes relapsing or unexplained neurological deterioration, with new CSF antibodies against N-Methyl-D-aspartate receptor (NMDAR) or other neuronal surface proteins, and requires immunotherapy rather than antivirals.5

Given the role of inflammation and oedema in early HSV encephalitis mortality, and the benefits seen in murine models,6 steroids are often used in severe cases, although their effect on viral reactivation remains uncertain.7 A multicentre, randomised, double-blind trial of dexamethasone versus placebo was terminated early for slow recruitment after enrolling 41 patients.8 Although underpowered, the study showed no difference in 6-month outcomes (modified Rankin scale 0–2 vs 3–6).8 In this issue of The Lancet Neurology, Tom Solomon and colleagues9 report the results of a multicentre observer-blind randomised phase 3 trial of adjunctive dexamethasone in adults with HSV encephalitis, which is timely and has potential treatment implications. Patients were randomly assigned to intravenous dexamethasone (10 mg four times daily for 4 days) plus aciclovir (10 mg/kg three times daily for ≥14 days; dexamethasone group), or intravenous aciclovir alone (control group). Systemic steroid use within 30 days before hospital admission (but not after) was an exclusion criterion. The primary outcome was verbal memory at 26 weeks (Wechsler Memory Scale [WMS]-IV auditory memory index). Secondary outcomes, assessed at 30 days, 26 weeks, or 78 weeks, included cognitive evaluations, clinical endpoints (intensive care unit dependence, ventilator support, Glasgow Coma Scale score, hospital stay, incidence of epilepsy, and survival), disability, and non-observer-blinded functional measures (modified Rankin Scale, Barthel Index, Liverpool Outcome Score), and neuroimaging. NMDAR antibodies were tested across participants, albeit not uniformly, at baseline and 2 weeks, and at 26 weeks but only in serum.

94 patients were enrolled (47 per group); six were lost to follow-up at week 26 and seven withdrew consent, yielding a modified intention-to-treat population of 81 (39 in the dexamethasone group and 42 in the control group). Four patients in each group died from encephalitis, and seven (two in the dexamethasone group) were unable to complete the primary outcome due to severe neuropsychological impairment. Baseline characteristics were comparable, and the study did not find significant differences in the primary outcome, adverse events, or secondary outcomes. Persistent HSV PCR detection at 2 weeks was similar between groups (four [11%] of 36 patients in the dexamethasone group vs nine [21%] of 43 in the control group). The authors conclude that adjunct dexamethasone in adults with HSV encephalitis was safe but did not improve primary or secondary endpoints compared with aciclovir alone.

However, the study has notable limitations: the cohort was small, and protocol flexibility complicates interpretation. In the control group, 12 (29%) patients received dexamethasone (eight before and four after randomisation) and one patient in the dexamethasone group did not. Although sensitivity analyses excluding these patients did not change the primary outcome, sensitivity analyses were not done for secondary outcomes. Ten patients did not have baseline MRI assessment. Dexamethasone was initiated a median of 7 days (range 3–21; IQR 4–8) after hospital admission, precluding assessment of its effects on early inflammation and oedema; some patients probably received treatment after any potential benefit timeframe had passed. Evaluation of post-infectious autoimmunity was limited by testing only NMDAR antibodies, suboptimal timing, small sample sizes, and no predefined clinical assessments. Ideally, CSF neuronal antibodies should be assessed at the time of diagnosis of HSV encephalitis and from day 21 onwards, with evaluation of psychiatric symptoms between 30 and 60 days after HSV encephalitis onset; however, this was not done.5 Five (5%) patients, all in the dexamethasone group, were identified as developing post-infectious autoimmune encephalitis, well below the 20–25% reported in prospective studies.

The authors suggest that, since steroids do not appear to exacerbate HSV encephalitis, earlier use of steroids might be considered in all cases with suspected autoimmune encephalitis without waiting for a confirmed negative HSV PCR result. However, early administration (before day 3) was not assessed, and the doses of methylprednisolone—preferred over dexamethasone—typically administrated (eg, 1 g per day for 5 days) in autoimmune encephalitis far exceed the doses used in this trial (0·75 mg dexamethasone ≈ 4 mg methylprednisolone).10

In an exploratory post-hoc regression analysis, earlier dexamethasone administration was associated with reduced verbal memory scores. Using time to randomisation, this association appeared in the dexamethasone group but not in the control group, although between-group differences were not significant. As the authors note, these findings should be interpreted cautiously due to the exploratory design, potential confounding, small sample size, and delayed dexamethasone administration.

The authors should be commended for completing a study where previous attempts have failed. Their findings represent an important step toward future trials investigating early corticosteroid use in HSV encephalitis and its potential impact on post-infectious autoimmune encephalitis.

抱歉!评论已关闭.

×
腾讯微博